INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2016

Oral telomerase activator TA-65 significantly improved macular function over 1 year in patients with early age-related macular degeneration.

In a 1-year, double-blind, placebo-controlled study, 38 patients with early macular degeneration were randomly assigned to receive oral TA-65 or placebo. Macular function showed significant improvement in the TA-65 arm compared to placebo, manifest at 6 months and maintained at 1 year. Macular threshold sensitivity improved 0.97 dB compared to placebo (P = 0.02), and percent reduced thresholds lessened 8.2% compared to the placebo arm (P = 0.04). The authors noted this was a pilot study and a larger study is planned.

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
38 patients with early age-related macular degeneration
What was measured
Macular functions via micro-perimetry

THE PAPER

Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study.

Dow CT, Harley CB. Clin Ophthalmol, 2016.

PubMed 26869760 ↗DOI 10.2147/opth.s100042 ↗

Healthy aging & longevityOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.